Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma

Cancer Journal

Volumn 14, Issue 4, 2008, Pages 269-275

  Leong, C N ^a,b   Chung, Hans T ^a,b   Lee, K M ^a,b   Shakespeare, Thomas P ^a,b   Mukherjee, Rahul K ^a,b   Wong, L C ^a   Lu, Jiade J ^a   Tey, J ^a,b   Lim, Robert ^a   So, J B Y ^a   Back, Michael F ^a,b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

Adjuvant chemoradiation; D2 resection; Gastric adenocarcinoma

Indexed keywords

FLUOROURACIL; FOLINIC ACID; ANTINEOPLASTIC ANTIMETABOLITE; VITAMIN B COMPLEX;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTRECTOMY; GASTROINTESTINAL SYMPTOM; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NOMENCLATURE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INDUCED EMESIS; RADIATION RESPONSE; RETROSPECTIVE STUDY; STOMACH ADENOCARCINOMA; THERAPY DELAY; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; LYMPHADENECTOMY; MIDDLE AGED; RISK FACTOR; STOMACH TUMOR; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUOROURACIL; GASTRECTOMY; HUMANS; LEUCOVORIN; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VITAMIN B COMPLEX; YOUNG ADULT;

EID: 57849098234     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318178d23a     Document Type: Article

References (28)

1. Lee HP, Ling A, Chow KW, et al. Singapore Cancer Registry, Interim Report: Trends in Cancer Incidence in Singapore 2001-2005. In: Office NRoD, ed 2007.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
3. MacDonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730.
4. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
5. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer. 1999;35:1059-1064.
6. Hallissey MT, Dunn JA, Ward LC, et al. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resect-able gastric cancer: five-year follow-up. Lancet. 1994;343:1309-1312.
7. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993;11:1441-1447.
8. MacDonald JS, Smalley SR, Benedetti J, et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: update of the results of Intergroup Study INT-0116 (SWOG 9008) [Abstract]. Gastrointestinal Cancers Symposium Program/Proceedings, American Society of Clinical Oncology 2005:106.
9. Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy - Japan Clinical Oncology Group Study 9501. J Clin Oncol. 2004;22:2767-2773.
10. Sasako M, Sano T, Yamamoto S, et al. Randomized phase III trial of standard D2 versus D2 + para-aortic lymph node (PAN) dissection (D) for clinically M0 advanced gastric cancer: JCOG9501. J Clin Oncol. 2006;24:LBA4015.
11. Kim S, Lim DH, Lee J, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. IntJ Radiat Oncol Biol Phys. 2005;63: 1279-1285.
12. Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006;7:309-315.
13. Smalley SR, Gunderson L, Tepper J, et al. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int J Radiat Oncol Biol Phys. 2002;52:283-293.
14. Back MF, Premsenthil S, Wynne CJ, et al. Introducing the Intergroup 0116 protocol of adjuvant chemo-radiotherapy in gastric cancer into clinical practice. Clin Oncol (R Coll Radiol). 2003;15:378-382.
15. Chung HT, Shakespeare TP, Wynne CJ, et al. Evaluation of a radiotherapy protocol based on INT0116 for completely resected gastric adenocarcinoma. Int J Radiat Oncol Biol Phys. 2004;59:1446-1453.
16. Sasako M, Saka M, Fukagawa T, et al. Surgical treatment of advanced gastric cancer: Japanese perspective. Dig Surg. 2007;24:101-107.
17. Ohgaki M, Toshio T, Akeo H, et al. Effect of extensive lymph node dissection on the survival of early gastric cancer. Hepatogastroenterology. 1999;46:2096-2099.
18. McCulloch P, Nita ME, Kazi H, et al. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Co-chrane Database Syst Rev. 2004:CD001964.
19. Cozzaglio L, Doci R, Celotti S, et al. Gastric cancer: extent of lymph node dissection and requirements for a correct staging. Tumori. 2004; 90:467-472.
20. Edwards P, Blackshaw GR, Lewis WG, et al. Prospective comparison of D1 vs modified D2 gastrectomy for carcinoma. Br J Cancer. 2004;90: 1888-1892.
21. Onate-Ocana LF, Aiello-Crocifoglio V, Mondragon-Sanchez R, et al. Survival benefit of D2 lympadenectomy in patients with gastric adenocarcinoma. Ann Surg Oncol. 2000;7:210-217.
22. Yildirim E, Celen O, Berberoglu U. The Turkish experience with curative gastrectomies for gastric carcinoma: is D2 dissection worthwhile? J Am Coll Surg. 2001;192:25-37.
23. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79: 1522-1530.
24. Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345:745-748.
25. Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22: 2069-2077.
26. Lewis WG, Edwards P, Barry JD, et al. D2 or not D2? The gastrectomy question. Gastric Cancer. 2002;5:29-34.
27. Degiuli M, Sasako M, Calgaro M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol. 2004;30:303-308.
28. Leong CN, Shakespeare TP, Mukherjee RK, et al. Efficacy of an integrated continuing medical education (CME) and quality improvement (QI) program on radiation oncologist (RO) clinical practice. Int J Radiat Oncol Biol Phys. 2006;66:1457-1460.